This segment focuses on the research, development, and commercialization of innovative medicines for neurological and immunological diseases. UCB, the primary operating company, utilizes advanced technologies such as monoclonal antibodies and small molecules to target specific disease pathways. Research and development activities include clinical trials for various indications, including epilepsy, Parkinson's disease, and autoimmune disorders. The segment's products, such as Cimzia, Briviact, and Vimpat, address significant unmet medical needs, improving patient outcomes and quality of life. Market positioning is strong due to UCB's established presence and pipeline of potential treatments. Future opportunities include expanding into new therapeutic areas and developing personalized medicine approaches. Regulatory aspects involve obtaining approvals from global health authorities. Partnerships and collaborations are crucial for advancing research and expanding market reach.